Cytovance Biologics, Pamlico Biopharma Enter Into Manufacturing Agreement

Feb 20, 2014

Digital Journal

Cytovance Biologics Inc., a full-service CMO of mammalian and microbial biologics, has entered into a development and manufacturing agreement with Pamlico Biopharma Inc., an Oklahoma City-based clinical stage biopharmaceutical company. Pamlico Biopharma has developed a group of three human IgG monoclonal antibodies intended for the treatment of Streptococcus pneumoniae infections. Pamlico has contracted Cytovance Biologics as its CMO to develop a production cell line from the protein's amino acid sequence for GMP manufacture of phase I clinical material. Read the full story

Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments